J. Fisher

发表

Multiparameter precursor analysis of T-cell responses to antigen.

P. Wallace, N. Bercovici, A. Givan, 2003, Journal of immunological methods.

Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells.

J. Fisher, R. Graziano, P. Guyre, 1997, Journal of immunology.

Fc receptor for IgG (FcyRl), blocks phagocytosis, and modulates receptor expression

P. Wallace, J. Fisher, L. Vitale, 1997 .

NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors

J. Fisher, M. Ernstoff, Tong Zhang, 2017, Molecular Cancer Therapeutics.

Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens.

J. Fisher, N. Alter, P. Guyre, 1992, Journal of immunology.

Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

J. Fisher, M. Ernstoff, C. Fadul, 2009, Cancer letters.

Vaccine-based immunotherapy for glioblastoma.

J. Fisher, M. Ernstoff, C. Fadul, 2013, CNS oncology.

Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy

J. Gui, C. Tomlinson, J. Fisher, 2012, PloS one.

Developing a RationalTumorVaccineTherapy for Renal Cell Carcinoma: ImmuneYin andYang

A. Schned, T. Crocenzi, J. Fisher, 2007 .

Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.

A. Schned, T. Crocenzi, J. Fisher, 2005, Clinical immunology.

Rapid Communication Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients i

A. Schned, T. Crocenzi, J. Fisher, 2005 .

Tracking antigen‐driven responses by flow cytometry: Monitoring proliferation by dye dilution

P. Wallace, K. Muirhead, J. Fisher, 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma

B. Christensen, A. Gaur, J. Fisher, 2017, Cancer Immunology, Immunotherapy.

A bispecific antibody, MDX-H210, was developed to target cytotoxic effector cells expressing Fcy receptor type I (Fc'yRI, CD64) to HER2lneu

P. Wallace, J. Fisher, T. Keler, 2006 .

Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications.

P. Wallace, M. Waugh, J. Fisher, 2002, Journal of immunological methods.

Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cells.

J. Fisher, M. Ernstoff, L. Lewis, 2009, Cytotherapy.

Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.

J. Gui, J. Fisher, M. Ernstoff, 2016, Anticancer research.

Erratum: A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens (Journal of Immunological Methods 230 (1999) (99-112) PII: S0022175999001362)

P. Wallace, A. Givan, M. Waugh, 2000 .

The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer

P. Wallace, M. Waugh, J. Fisher, 2002, Cancer Chemotherapy and Pharmacology.

Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcγRI), blocks phagocytosis, and modulates receptor expression

P. Wallace, J. Fisher, L. Vitale, 1997, Journal of leukocyte biology.

Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032

J. Fisher, M. Ernstoff, C. Brinckerhoff, 2014, Pigment cell & melanoma research.

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival

J. Fisher, M. Ernstoff, R. Noelle, 2018, Cancer Immunology, Immunotherapy.

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

J. Fisher, P. Kaufman, R. Graziano, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours

J. Fisher, M. Ernstoff, A. Beelen, 2013, Journal of chemotherapy.

Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy

H. Wishart, T. Tosteson, J. Gui, 2011, Journal of immunotherapy.

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.

J. Gui, J. Fisher, M. Ernstoff, 2011, Neuro-oncology.

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients

A. Schned, T. Crocenzi, J. Fisher, 2009, Clinical Cancer Research.

Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-dendritic Cell Vaccine with Aldesleukin (interleukin 2) and Ifn-α2a Therapy in Metastatic Renal Cell Carcinoma Patients Section of Urology, Departments Of

A. Schned, T. Crocenzi, J. Fisher, 2022 .

Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang

A. Schned, T. Crocenzi, J. Fisher, 2007, Clinical Cancer Research.

Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy.

J. Gui, J. Fisher, M. Ernstoff, 2021, Nature cancer.

Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy

J. Gui, J. Fisher, M. Ernstoff, 2021, Nature Cancer.

Taxanes Synergize with the Bispecific Antibody MDXH447 to Enhance Antibody-Dependent Cell-Mediated Cytotoxicity

M. Waugh, J. Fisher, M. Ernstoff, 2003, Journal of chemotherapy.

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.

J. Fisher, M. Ernstoff, P. Kaufman, 1995, Journal of hematotherapy.

Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.

Jennifer J. Gibson, E. Wallen, A. Schned, 2004, Journal of Urology.

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.

M. Atkins, T. Crocenzi, J. Fisher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).

J. Fisher, M. Fanger, E. Ball, 1992, Journal of hematotherapy.

A. Schned, J. Fisher, M. Ernstoff, 2006, The Prostate.

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

P. Wallace, J. Fisher, T. Keler, 1997, Cancer research.

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

J. Fisher, M. Ernstoff, Lei Sun, 2020, Journal for ImmunoTherapy of Cancer.

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens.

P. Wallace, A. Givan, M. Waugh, 1999, Journal of immunological methods.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

J. Fisher, M. Ernstoff, C. Fadul, 2016, Melanoma research.

Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine

J. Gui, C. Tomlinson, J. Fisher, 2012, PloS one.

Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.

H. Wishart, J. Gui, J. Kleen, 2015, Neuro-oncology.

Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.

P. Wallace, A. Givan, M. Waugh, 2001, Journal of immunological methods.

Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo

J. Fisher, M. Ernstoff, S. Wrzesinski, 2013, Experimental Hematology & Oncology.

Dye Dilution Proliferation Assay: Application of the DDPA to Identify Tumor-Specific T Cell Precursor Frequencies in Clinical Trials

A. Givan, J. Fisher, M. Ernstoff, 2007, Immunological investigations.

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu.

P. Wallace, M. Waugh, J. Fisher, 2001, Journal of immunological methods.

Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells.

P. Wallace, N. Bercovici, A. Givan, 2004, Methods in molecular biology.

Letter to the editor

J. Fisher, M. Ernstoff, C. Fadul, 2014, Journal of Immunotherapy for Cancer.

M. Atkins, T. Crocenzi, J. Fisher, 2010, Journal of Clinical Oncology.

Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

J. Fisher, M. Ernstoff, C. Fadul, 2009, Cancer letters.